Joost Bart

6.5k citations

81 papers · 4.9k indexed · 2 hit papers · h-index 29

Oncology top 1%
- Drug Transport and Resistance Mechanisms 13
- HER2/EGFR in Cancer Research 10
Cancer Research top 2%
- Breast Cancer Treatment Studies 9
Radiology, Nuclear Medicine and Imaging top 1%
Reproductive Medicine top 2%
- Ovarian cancer diagnosis and treatment 18
Neurology top 2%
Pediatrics, Perinatology and Child Health
- Pharmacological Effects and Toxicity Studies 12
Genetics
- BRCA gene mutations in cancer 10
Obstetrics and Gynecology
- Endometrial and Cervical Cancer Treatments 8
Psychiatry and Mental health
- Epilepsy research and treatment 7

Co-authors: N. Harry Hendrikse Willem Vaalburg Gooitzen M. van Dam Rick G. Pleijhuis Elisabeth G.E. de Vries Johannes S. de Jong Lucia M.A. Crane Antoon T. M. Willemsen
Cited by: Oncology Cancer Research Radiology, Nuclear Medicine and Imaging
Journals: Histopathology (4 papers)The Journal of Clinical Pharmacology (3 papers)Gynecologic Oncology (3 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Joost Bart

76 papers receiving 4.8k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Joost Bart

Since Specialization

Citations

This map shows the geographic impact of Joost Bart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joost Bart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joost Bart more than expected).

Fields of papers citing papers by Joost Bart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joost Bart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joost Bart. The network helps show where Joost Bart may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Joost Bart, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Joost Bart Line = papers co-authored together Joost Bart links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Vvax001, a Therapeutic Vaccine, for Patients with HPV16-Positive High-grade Cervical Intraepithelial Neoplasia: A Phase II Trial Clinical Cancer Research ·Z. Li,Rozanna Mulyani,표홍렬,Annegé Vledder,Nienke van Rooij,Annechien Plat,Е А Тарасова,Sterre T. Paijens,Lorian Slagter‐Menkema,Ed Schuuring,橋本和宣,Jos G. W. Kosterink,Bart‐Jan Kroesen,Jan Wilschut,Toos Daemen,Joost Bart,Hans W. Nijman,Marco de Bruyn,Refika Yigit	2025	4
2	Spatiotemporal Immune Landscape and Long-term Immune Memory in POLE-Mutant Endometrial Cancer at the Single-Cell Level Cancer Immunology Research ·표홍렬,Marta Requesens,Nienke van Rooij,Hagma H. Workel,博昭蓮見,Annechien Plat,René Wardenaar,Diana C.J. Spierings,Floris Foijer,David N. Church,Joost Bart,Hans W. Nijman,Marco de Bruyn	2025	0
3	BRCA1/2 Testing Landscape in Ovarian Cancer: A Nationwide, Real-World Data Study Cancers ·denes spätgeometrisches,Joost Bart,Marian J.E. Mourits,Stefan M. Willems,Annemieke H. van der Hout,Arja ter Elst,Geertruida H. de Bock	2024	2
4	Increased Interferon Signaling in Vaginal Tissue of Patients With Primary Sjögren Syndrome The Journal of Rheumatology ·Annie Visser,Jolien F. van Nimwegen,Geoffrey O‘Brien,S.C. Liefers,Karin van der Tuuk,Marian J.E. Mourits,Gilles F.H. Diercks,Joost Bart,Bert van der Vegt,Léon C.L.T. van Kempen,Hendrika Bootsma,Frans G. M. Kroese,Gwenny M. Verstappen	2024	2
5	Delayed Diagnosis of Disseminated Invasive Aspergillosis with Purulent Myocarditis in an Immunocompromised Host Infectious Disease Reports ·Ella McKinley Wilson,Maarten W. Nijsten,Joost Bart,Parsa Pahlavan,Bhanu Sinha,Douwe F. Postma	2024	0
6	Does “One Size Fits All”? Rethinking FIGO Depth of Invasion Measurements in Vulvar Cancer International Journal of Gynecological Pathology ·Maaike C.G. Bleeker,Tjalling Bosse,Koen Van de Vijver,Joost Bart,Hugo M. Horlings,Trudy Jonges,Nicole C.M. Visser,Loes Kooreman,Johan Bulten,Patricia C. Ewing‐Graham	2024	0
7	Incidence of gynaecological cancer during the COVID-19 pandemic: A population-based study in the Netherlands Cancer Epidemiology ·Mile J. Milekić,Cor D. de Kroon,Joost Bart,Hans W. Nijman,Maaike A. van der Aa	2023	2
8	BRCA1/2 testing rates in epithelial ovarian cancer: a focus on the untested patients International Journal of Gynecological Cancer ·denes spätgeometrisches,Marian J.E. Mourits,Joost Bart,Arja ter Elst,Natalia Chalenko,Annemieke H. van der Hout,Amna Imran,Geertruida H. de Bock	2023	1
9	The risk of lymph node metastasis in the new FIGO 2018 stage IA cervical cancer with >7 mm diameter Journal of Gynecologic Oncology ·Osama El Demerdesh,Refika Yigit,Maaike C.G. Bleeker,Joost Bart,Jacobus van der Velden,Constantijne H. Mom	2023	2
10	Trends in incidence, treatment, survival and subsequent breast cancer in lobular carcinoma in situ in the Netherlands: A population-based analysis The Breast ·Marissa C. van Maaren,G. K. Ternet,Jeannette G. van Manen,Marian B. E. Menke‐Pluijmers,Jeroen Veltman,Joost Bart,Pieter J. Westenend,Sabine Siesling	2021	10
11	Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach Breast Cancer Research and Treatment ·Tim Dekker,Shojiro Ikeguchi,Gerrit K. Hooijer,Sybren L. Meijer,Jelle Wesseling,James E. Boers,Ed Schuuring,Joost Bart,Joost van Gorp,Peter Bult,Sietske A. Riemersma,Carolien H. M. van Deurzen,Hein F.B.M. Sleddens,Wilma E. Mesker,Judith R. Kroep,Vincent T.H.B.M. Smit,Marc J. van de Vijver	2015	16
12	A validated web-based nomogram for predicting positive surgical margins following breast-conserving surgery as a preoperative tool for clinical decision-making The Breast ·Rick G. Pleijhuis,A.B.G. Kwast,Liesbeth Jansen,Jakob de Vries,Rosanne Lanting,Joost Bart,Theo Wiggers,Gooitzen M. van Dam,Sabine Siesling	2013	43
13	High Concordance of 5 HER2 In Situ Hybridization Methods with Abbott FISH. Laboratory Investigation ·James E. Boers,Horan Liu,Mary Redlin,Clemens Prinsen,C. van Krimpen,Joost Bart,Elise M.J. van der Logt,Taif AlSomaida	2011	1
14	Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: A single‐arm phase II study International Journal of Cancer ·Renee Vermeij,Ninke Leffers,Baukje‐Nynke Hoogeboom,Pickering Ad,Rinze Wolf,Anna K.L. Reyners,Barbara H. W. Molmans,Harry Hollema,Joost Bart,Jan W. Drijfhout,Jaap Oostendorp,Ate G.J. van der Zee,Cornelis J.M. Melief,Sjoerd H. van der Burg,Toos Daemen,Hans W. Nijman	2011	72
15	Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human resultsbreakdown → Nature Medicine ·Gooitzen M. van Dam,George Themelis,Lucia M.A. Crane,Niels J. Harlaar,Rick G. Pleijhuis,Wendy Kelder,Athanasios Sarantopoulos,Johannes S. de Jong,Henriëtte J.G. Arts,Ate G.J. van der Zee,Joost Bart,Philip S. Low,Vasilis Ntziachristos	2011	1262
16	Expression of the stem cell marker ALDH1 in BRCA1 related breast cancer PubMed ·Marise R. Heerma van Voss,Petra van der Groep,Joost Bart,Elsken van der Wall,P. J. van Diest	2011	27
17	Obtaining Adequate Surgical Margins in Breast-Conserving Therapy for Patients with Early-Stage Breast Cancer: Current Modalities and Future Directions Annals of Surgical Oncology ·Rick G. Pleijhuis,Maurits Graafland,Jakob de Vries,Joost Bart,Johannes S. de Jong,Gooitzen M. van Dam	2009	255
18	P-gp and MRP1 Expression in Parathyroid Tumors Related to Histology, Weight and ^99 mTc-Sestamibi Imaging Results Experimental and Clinical Endocrinology & Diabetes ·Brittany Balsamo,H. Hollema,Sibusiso Malinga,Joost Bart,Adrienne H. Brouwers,John Th. M. Plukker	2009	8
19	Development and Characterization of Clinical-Grade ⁸⁹Zr-Trastuzumab for HER2/neu ImmunoPET Imaging Journal of Nuclear Medicine ·Eli Dijkers,Jos G. W. Kosterink,Rudolf Lütke Schwienhorst,Lars R. Perk,Guus A.M.S. van Dongen,Joost Bart,Johan R. de Jong,Elisabeth G.E. de Vries,Marjolijn N. Lub–de Hooge	2009	271
20	Positron Emission Tomography Studies on Binding of Central Nervous System Drugs and P-Glycoprotein Function in the Rodent Brain Molecular Imaging and Biology ·Philip H. Elsinga,N. Harry Hendrikse,Joost Bart,Aren van Waarde,Willem Vaalburg	2004	39

About Joost Bart

Joost Bart is a scholar working on Reproductive Medicine, Oncology, Obstetrics and Gynecology, Cancer Research and Pediatrics, Perinatology and Child Health, having authored 81 papers that have together received 4.9k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (18 papers), Drug Transport and Resistance Mechanisms (13 papers), Pharmacological Effects and Toxicity Studies (12 papers), BRCA gene mutations in cancer (10 papers), HER2/EGFR in Cancer Research (10 papers), Breast Cancer Treatment Studies (9 papers), Endometrial and Cervical Cancer Treatments (8 papers) and Epilepsy research and treatment (7 papers). The work is most often cited by research in Oncology (1.7k citations), Cancer Research (760 citations), Radiology, Nuclear Medicine and Imaging (1.1k citations), Reproductive Medicine (384 citations) and Neurology (344 citations). Joost Bart has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include N. Harry Hendrikse, Willem Vaalburg, Gooitzen M. van Dam, Rick G. Pleijhuis, Elisabeth G.E. de Vries, Johannes S. de Jong, Lucia M.A. Crane, Antoon T. M. Willemsen, Vasilis Ntziachristos and Niels J. Harlaar. Their work appears in journals such as Histopathology, The Journal of Clinical Pharmacology, Gynecologic Oncology, Breast Cancer Research and OncoImmunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact